Clinical trials: Submucosal Tumors
Superficial Esophageal Cancers
Status of Superficial Esophageal Cancers Treated by Endoscopy "OESOFARE"
In 2013, esophageal cancer was the 9th cause of cancer in the world and the 6th in terms of cancer mortality. The prognosis of this cancer varies according to geographical areas, but in Europe and the USA, the 5-year survival…
- Trial name
- OESOFARE (NCT03674801)
- Where
- France
- Volunteers
- 151 people
- Sponsor
- Nantes University Hospital
Colorectal Cancer
Does Routine Submucosal Injection Improve Complete Resection of 4-20 mm Neoplastic Colorectal Polyps?
This is a prospective, multi-endoscopist, single center, clinical study at tertiary referral center that addresses an important current challenge in the prevention of colorectal cancer (CRC), namely, how to improve the complete…
- Trial name
- NCT04548947
- Testing
- Cold snare polypectomy in conjunction with a submucosal injection
- Where
- Canada
- Volunteers
- 429 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Stomach Neoplasms
The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD
This will be a single-centre, randomised, endoscopist-blind, parallel-group study in patients who are scheduled endoscopic submucosal dissection (ESD) for gastric mucosal lesion.
- Trial name
- NCT02730533
- Testing
- Esomeprazole, No PPI treatment
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastrointestinal Neoplasm
Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection
The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection…
- Trial name
- NCT06134687
- Testing
- Endoscopic Submucosal Dissection, Novel Rigidizing Overtube
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- Baylor College of Medicine
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
This single-center, prospective, single-arm study will evaluate whether giving neoadjuvant chemoimmunotherapy can safely shrink esophageal cancer and allow organ-preserving endoscopic removal in selected patients.
- Trial name
- Endosurgery-02 (NCT07317609)
- Testing
- Tislelizumab, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric Cancer Stage
Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China
Background: The main treatment methods for early gastric cancer (EGC) include endoscopic submucosal dissection (ESD) and radical gastrectomy.
- Trial name
- NCT06869356
- Testing
- D2 gastrectomy
- Where
- China
- Volunteers
- 1,291 people
- Sponsor
- Beijing Friendship Hospital
Rectal Neuroendocrine Tumors
Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm
The aim of this study is evaluating and safety and efficacy between the modified double snare EMR and ESD. It is intended to prove that for rectal neuroendocrine tumors within 1 cm, the complete resection rate of the mDS-EMR is…
- Trial name
- NCT07373015
- Testing
- modified double snare assisted endoscopic mucosal resection, endoscopic submucosal dissection
- Volunteers
- 118 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Esophageal Lesion, Barrett Esophagus
Endoscopic Submucosal Dissection (ESD)
This registry is to evaluate the procedural and clinical outcomes in patients undergoing endoscopic submucosal dissection. All patients will receive standard of medical care and no experimental interventions will be performed.
- Conditions
- Esophageal Lesion, Barrett Esophagus, Gastrointestinal Lesions
- Trial name
- ESD (NCT05468008)
- Testing
- Endoscopic Submucosal Dissection
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- AdventHealth
Esophageal Squamous Cell Neoplasm
RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection
Esophageal cancer is a highly lethal disease, and its incidence is still increasing in the world. Recent advances in image-enhanced techniques such as Lugol chromoendoscopy and narrow band imaging, the number of patients with…
- Trial name
- NCT03183115
- Testing
- Radiofrequency ablation, Endoscopy, Lugol's Solution (1.5%)
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- E-DA Hospital
Colorectal Neoplasia, Colorectal Superficial Neoplasia
Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion
Colorectal endoscopic submucosal dissection (ESD) enables en bloc resection of large superficial colorectal neoplasia but remains technically demanding and may be limited by suboptimal visualization, intraprocedural bleeding…
- Conditions
- Colorectal Neoplasia, Colorectal Superficial Neoplasia, Colorectal Precancerous Lesions
- Trial name
- TIDE (NCT07490574)
- Testing
- Underwater ESD (UESD), Conventional Gas-Assisted ESD (GESD)
- Where
- Italy
- Volunteers
- 295 people
- Sponsor
- University of Roma La Sapienza
Gastric Neoplasm
The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
Endoscopic submucosal dissection (ESD) is an effective treatment for early gastric cancer or premalignant lesions in the stomach.
- Trial name
- NCT02235246
- Testing
- Magnesium Sulfate, Normal saline
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Neoplasms, Colorectal
Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions.
EMR and ESD are both effective and safe and are associated with a very low risk of procedure related mortality when performed for colorectal laterally spreading lesions (LSL).
- Trial name
- intERsection (NCT04593407)
- Testing
- Endoscopic mucosal resection (EMR), Endoscopic submucosal dissection (ESD)
- Where
- Spain
- Volunteers
- 236 people
- Sponsor
- José Carlos Marín Gabriel
Colorectal Neoplasms, Perforation of Rectum
Outcomes of Perforation After Colorectal Endoscopic Submucosal Dissection
Endoscopic resection of superficial colorectal neoplasms decrease risk of colorectal cancer. En bloc resection is necessary for large superficial lesions with risk of superficial submucosal cancer and is advised if feasible for…
- Conditions
- Colorectal Neoplasms, Perforation of Rectum, Perforation Colon
- Trial name
- NCT05728710
- Testing
- Endoscopic submucosal dissection
- Where
- 13 sites in Belgium, France
- Volunteers
- 350 people
- Sponsor
- Central Hospital, Nancy, France
Gastric Adenoma, Early Gastric Cancer
The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer
Endoscopic submucosal dissection (ESD) is an advanced technique that enables en bloc resection of superficial tumors in the gastrointestinal tract.
- Trial name
- NCT02243618
- Testing
- Polaprezinc, Rebamipide
- Where
- South Korea
- Volunteers
- 153 people
- Sponsor
- Yonsei University
Digestive System Diseases
Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms
Endoscopic submucosal dissection (ESD) is a newly developed technique in the field of endoscopic treatment for GI neoplasms, because of its high rate of en bloc resection.
- Trial name
- NCT01378507
- Testing
- endoscopic submucosal dissection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese PLA General Hospital
Early Gastric Cancer, Gastric Adenoma
Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection
Endoscopic submucosal dissection is commonly performed under light to moderate sedation, and minimizing patient movement is of key importance for successful outcome.
- Trial name
- NCT02504164
- Testing
- midazolam 0.02mg/kg, No premedication
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Yonsei University
Superficial Esophageal Cancer
A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
The purpose of this study is to evaluate the efficacy and safety of esophageal epithelial regenerative treatment by the transplantation of the product, CLS2702C, to the esophageal wound site after extensive ESD for superficial…
- Trial name
- NCT04689594
- Testing
- CLS2702C/CLS2702D
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- CellSeed Inc.
Esophagus Cancer
Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer
This multicenter, prospective observational cohort study has the potential to optimize individualized chemoradiotherapy regimen for early-stage esophageal cancer patients who have received endoscopic submucosal dissection.
- Trial name
- ESCORT (NCT06385717)
- Testing
- chemo-radiation
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Barrett's Esophagus, Intestinal Dysplasia
Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial
ESD (Endoscopic Sub-mucosal Dissection)is the first-intent method to treat superficial neoplasms of the digestive tract at it allows an en-bloc R0 resection.
- Conditions
- Barrett's Esophagus, Intestinal Dysplasia, Esophageal Dysplasia, Colorectal Neoplasms
- Trial name
- NESTIS (NCT01913223)
- Testing
- Nestis® jet injector system with a bi-functional catheter
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Subepithelial Lesions
Diagnostic Accuracy of EUS for Colorectal Submucosal Masses
This study aims to evaluate the diagnostic accuracy of endoscopic ultrasound (EUS) for colorectal submucosal tumors/lesions (SMTs/SELs) and to identify factors associated with correct EUS diagnosis.
- Trial name
- NCT07351890
- Testing
- Endoscopic Ultrasound (EUS) Assessment
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Run-hua Li